Drug Trial Radar · NCT01846611
A Study Comparing the Combination of Trabectedin (YONDELIS) and DOXIL/CAELYX With DOXIL/CAELYX for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Last checked: Nov 19, 2026Latest source record: Apr 1, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
581
Actual
Start
Oct 16, 2013
Primary completion
Jan 18, 2018
Study completion Nov 16, 2018
Sponsor
- Lead sponsor
- Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
- Sponsor type
- Industry
- Collaborators
- PharmaMar
- First posted
- May 3, 2013
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- Female only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to assess the efficacy and safety of trabectedin+DOXIL as a third-line chemotherapy regimen (treatment) in patients with platinum-sensitive advanced-relapsed epithelial ovarian, primary peritoneal, or fallopian tube cancer who received 2 previous lines of platinum-based chemotherapy.
Conditions
- Ovarian Neoplasms
- Peritoneal Neoplasms
- Fallopian Tube Neoplasms
Interventions
TrabectedinDrug
1.1 mg/m\^2 administered intravenously over approximately 3 hours on Day 1 of each 21-day treatment cycle.
DOXILDrug
30 mg/m\^2 administered intravenously over approximately 90 minutes on Day 1 of each 21-day treatment cycle.
DexamethasoneDrug
20 mg administered intravenously on Day 1 of each 21-day treatment cycle approximately 30 minutes prior to study drug infusion.
DOXILDrug
50 mg/m\^2 administered intravenously over approximately 90 minutes on Day 1 of each 28-day treatment cycle.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall Survival (OS)Time frame: Up to 4.3 years
Locations
138 sites in 10 countries. Site status is shown where the registry gives one.
Site not named
Birmingham, Alabama
Site not named
Phoenix, Arizona
Site not named
Scottsdale, Arizona
Site not named
Sedona, Arizona
Site not named
Tucson, Arizona
Site not named
Hot Springs, Arkansas
Site not named
Greenbrae, California
Site not named
La Jolla, California
Site not named
Los Angeles, California
Site not named
Orange, California
Site not named
Sacramento, California
Site not named
Englewood, Colorado
Site not named
New Britain, Connecticut
Site not named
New Haven, Connecticut
Site not named
Stamford, Connecticut
Site not named
Fort Myers, Florida
Site not named
Jacksonville, Florida
Site not named
Miami, Florida
Site not named
Sarasota, Florida
Site not named
St. Petersburg, Florida
Site not named
Tampa, Florida
Site not named
Atlanta, Georgia
Site not named
Savannah, Georgia
Site not named
Chicago, Illinois
Site not named
Park Ridge, Illinois
Site not named
Indianapolis, Indiana
Site not named
Louisville, Kentucky
Site not named
Covington, Louisiana
Site not named
New Orleans, Louisiana
Site not named
Scarborough, Maine
Site not named
Worcester, Massachusetts
Site not named
Detroit, Michigan
Site not named
Lansing, Michigan
Site not named
Duluth, Minnesota
Site not named
Edina, Minnesota
Site not named
Columbia, Missouri
Site not named
Kansas City, Missouri
Site not named
Hackensack, New Jersey
Site not named
Morristown, New Jersey
Site not named
New Brunswick, New Jersey
Showing 40 of 138 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.